Go to the list of all blogs
M. Benett's Avatar
published in Blogs
Nov 20, 2026
TickeronGET DAILY SIGNALS
Eli Lilly (LLY) vs Vanguard Health Care ETF (VHT): Momentum Against Diversification

Eli Lilly (LLY) vs Vanguard Health Care ETF (VHT): Momentum Against Diversification

Key Takeaways

  • LLY is a single pharmaceutical company, while VHT is a diversified exchange-traded fund (ETF) spanning large-, mid-, and small-cap U.S. healthcare stocks.
  • LLY has shown stronger recent momentum, trading near record highs on surging demand for its GLP-1 (glucagon-like peptide-1) obesity and diabetes drugs.
  • VHT offers broader diversification and lower single-company risk, with a modest dividend yield, but trails LLY's relative performance over recent months.
  • Tickeron AI Verdict: Between the two, the AI currently favors LLY based on stronger trend consistency and catalysts.
  • For more detail on either name, explore LLY Major News and LLY Today's Price Move, as well as VHT Major News and VHT Today's Price Move.
  • Discover how automated strategies are navigating this market by exploring Trending AI Robots.

Why Compare a Single Stock to a Sector ETF

Investors often face the choice between concentrated growth and broader diversification. LLY (Eli Lilly and Company) stands as one of the world's largest pharmaceutical firms and a leader in weight-loss and diabetes treatments. VHT (Vanguard Health Care ETF) tracks an index of U.S. healthcare companies across all sizes, delivering one-ticker exposure to the full sector. This comparison looks at relative performance, growth drivers, risk factors, and positioning to help evaluate which approach better fits different objectives right now.

Eli Lilly's Recent Momentum

Eli Lilly focuses on neuroscience, cardiometabolic health, oncology, and immunology. Its incretin franchise, led by Mounjaro and Zepbound, drove roughly two-thirds of revenue in the latest quarter. The company posted revenue near $24.4 billion, up about 39% year over year, and raised full-year guidance several times in 2026. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.

The shares have traded near all-time highs lately, helped by expanded Medicare access through the GLP-1 bridge program and international growth, including in China. Analyst ratings stay broadly positive with targets above current levels. Sentiment holds steady, though concentration risk stands out because a large revenue portion ties to a few key medicines, and future GLP-1 pricing pressure remains a topic of discussion.

Vanguard Health Care ETF's Steady Profile

VHT tracks the MSCI US Investable Market Health Care 25/50 Index. It holds hundreds of U.S. healthcare names across pharmaceuticals, biotechnology, medical devices, insurers, and providers. Broad diversification means no single company drives returns the way a large pharmaceutical holding can influence an individual stock.

In recent months VHT has advanced as healthcare stocks benefited from sector rotation, though gains have been more moderate than those of standout individual names. The fund features a low expense ratio and modest dividend yield. Lower single-stock concentration generally supports reduced volatility, with performance reflecting the sector aggregate rather than any one product or catalyst.

Head-to-Head: Concentration Versus Spread

The main difference comes down to focus versus breadth. LLY gives direct access to one of the strongest growth stories in pharmaceuticals, yet results and share price remain highly sensitive to a handful of products and GLP-1 pricing trends. VHT spreads exposure across the healthcare sector, tempering both upside and downside moves.

On growth and momentum, LLY shows a clear advantage with revenue growth near 39% and shares near record levels. VHT's relative performance has been positive but more measured, mirroring the sector average. On risk, VHT's wider holdings and lower concentration typically mean lower volatility, while LLY carries higher valuation and product-concentration considerations. Both draw from the same healthcare demand trends, but they translate those into returns in very different ways.

Tickeron AI Verdict

Based on factors such as trend consistency, earnings momentum, and identifiable growth catalysts, Tickeron's AI currently leans toward LLY in this matchup. Sustained revenue growth, repeated upward guidance revisions, and persistent relative strength against the broader market support a favorable technical and fundamental profile. The view remains probabilistic: LLY's narrow product focus and premium valuation introduce volatility that a diversified holding like VHT would help offset. Investors seeking higher-momentum exposure may align with the AI's preference, while those favoring broad, lower-volatility sector coverage may prefer VHT's structure.

Exploring Automated Strategies

I've found Tickeron's AI Trading Bots helpful when reviewing how different automated approaches handle current market conditions across healthcare names. The platform highlights bots with varying styles, timeframes, and performance statistics, updating the featured list as trends shift so traders can see strategies best aligned with prevailing conditions.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations

Related Ticker: LLY, VHT

LLY's RSI Oscillator peaks and leaves overbought zone

The 10-day RSI Indicator for LLY moved out of overbought territory on November 16, 2026. This could be a sign that the stock is shifting from an upward trend to a downward trend. Traders may want to look at selling the stock or buying put options. Tickeron's A.I.dvisor looked at 34 instances where the indicator moved out of the overbought zone. In 25 of the 34 cases the stock moved lower in the days that followed. This puts the odds of a move down at 74%.

Price Prediction Chart

Technical Analysis (Indicators)

Bearish Trend Analysis

The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 47 of 64 cases where LLY's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 73%.

The Momentum Indicator moved below the 0 level on November 18, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on LLY as a result. In 53 of 83 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 64%.

The Moving Average Convergence Divergence Histogram (MACD) for LLY turned negative on November 17, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 45 similar instances when the indicator turned negative. In 30 of the 45 cases the stock turned lower in the days that followed. This puts the odds of success at 67%.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where LLY declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 53%.

LLY broke above its upper Bollinger Band on October 29, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

Bullish Trend Analysis

The 10-day moving average for LLY crossed bullishly above the 50-day moving average on October 15, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 7 of 13 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 54%.

Following a +1.80% 3-day Advance, the price is estimated to grow further. Considering data from situations where LLY advanced for three days, in 261 of 371 cases, the price rose further within the following month. The odds of a continued upward trend are 70%.

The Aroon Indicator entered an Uptrend today. In 219 of 300 cases where LLY Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 73%.

Fundamental Analysis (Ratings)

The Tickeron Profit vs. Risk Rating rating for this company is 4 (best 1 - 100 worst), indicating low risk on high returns. The average Profit vs. Risk Rating rating for the industry is 60, placing this stock better than average.

The Tickeron Price Growth Rating for this company is 10 (best 1 - 100 worst), indicating outstanding price growth. LLY’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron SMR rating for this company is 14 (best 1 - 100 worst), indicating very strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron PE Growth Rating for this company is 59 (best 1 - 100 worst), pointing to average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Valuation Rating of 86 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: LLY's P/B Ratio (35.624) is slightly higher than the industry average of (-1.421). P/E Ratio (45.360) is within average values for comparable stocks, (21.700). Projected Growth (PEG Ratio) (1.170) is also within normal values, averaging (5.738). Dividend Yield (0.005) settles around the average of (0.038) among similar stocks. LLY's P/S Ratio (12.804) is very high in comparison to the industry average of (4.033).

Notable companies

The most notable companies in this group are Eli Lilly & Co (NYSE:LLY), Johnson & Johnson (NYSE:JNJ), ABBVIE (NYSE:ABBV), Merck & Co (NYSE:MRK), AstraZeneca PLC (NYSE:AZN), Amgen (NASDAQ:AMGN), Gilead Sciences (NASDAQ:GILD), Pfizer (NYSE:PFE), Bristol-Myers Squibb Co (NYSE:BMY), Biogen (NASDAQ:BIIB).

Industry description

The Major Pharmaceuticals industry includes companies that are involved in various processes of creating drugs to treat/prevent diseases. These companies engage in research, testing and manufacturing, as well as the distribution of pharmaceuticals into markets. Johnson & Johnson, Merck & Co., Inc., Pfizer Inc. and Novartis are among the largest companies in this category.

Market Cap

The average market capitalization across the Pharmaceuticals: Major Industry is 215.99B. The market cap for tickers in the group ranges from 4.8K to 1.21T. LLY holds the highest valuation in this group at 1.21T. The lowest valued company is NEWG at 4.8K.

High and low price notable news

The average weekly price growth across all stocks in the Pharmaceuticals: Major Industry was -13%. For the same Industry, the average monthly price growth was -10%, and the average quarterly price growth was -6%. OGN experienced the highest price growth at 0%, while SCLX experienced the biggest fall at -58%.

Volume

The average weekly volume growth across all stocks in the Pharmaceuticals: Major Industry was 26%. For the same stocks of the Industry, the average monthly volume growth was 14% and the average quarterly volume growth was 33%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 59
P/E Growth Rating: 33
Price Growth Rating: 46
SMR Rating: 59
Profit Risk Rating: 59
Seasonality Score: 17 (-100 ... +100)
Real Time Patterns 3
View a ticker or compare two or three
Interact to see
Advertisement
A.I.Advisor
published price charts
A.I. Advisor
published General Information

General Information

a manufacturer of pharmaceutical products

Industry PharmaceuticalsMajor

Industry
Pharmaceuticals Major
Address
Lilly Corporate Center
Phone
+1 317 276-2000
Employees
50000
Web
https://www.lilly.com
Interact to see
Advertisement
SDD is an inverse leveraged ETF (exchange-traded fund) built to return roughly -2x the daily move of the S&P SmallCap 600 Index, making it a tactical hedging tool rather than a long-term holding. XXX is an asset-allocation ETF that blends roughly 75% S&P 500 large-cap equities with a 25% sleeve of XRP, a major cryptocurrency, aiming for capital appreciation.
AMD jumped +2.42%, rising $12.81 to $542.95 from Wednesday's close of $530.14, in early regular-session trading Thursday after extending gains built during premarket. The catalyst was Anthropic's IPO, priced at $83 a share above its marketed range and raising $81.3 billion in the largest listing on record; the debut revived sentiment across AI hardware names, and AMD is both an Anthropic supplier and a $2.5 billion investor in the lab.
ROM is an established, leveraged exchange-traded fund (ETF) that targets twice (2x) the daily return of the S&P Technology Select Sector Index, while XXX is a recently launched blended ETF pairing large-cap U.S. equities with XRP exposure. ROM benefits from deep liquidity and roughly $1.1 billion in AUM (assets under management); XXX remains far smaller, with assets measured in the hundreds of thousands of dollars.
NVIDIA (NVDA) has declined roughly 32.6% over the last 30 days, falling from $216.47 on October 20 to around $146 in mid-November trading. The selloff was triggered by the surprise resignation of founder and CEO Jensen Huang, along with governance, regulatory, and China-related concerns.
Micron shares slid from Thursday's $690.44 close to $635.41, a -7.97% loss, deepening during Friday's regular session after an already soft premarket. The decline was sector-driven, not company-specific: investors kept unwinding AI exposure as Anthropic fell back after its debut, while hawkish Fed comments and doubts about Nvidia's leadership and AI spending returns pressured chip valuations.